Eli Lilly's Deal Juggernaut Meets a Cancer Signal: Why the Market Hardly Blinked

Eli Lilly opened June with a flurry of deal-making that would have dominated headlines in any normal week — three separate licensing and collaboration agreements signed on a single trading day. Yet the stock barely budged, slipping roughly 2% to around €930, a modest pullback after a torrid May that saw shares surge more than 14%. The muted reaction speaks volumes about the scale of expectations that now surround the US pharma giant.

The three pacts — with Sweden's Camurus, China's Haisco Pharmaceutical, and South Korea's Hanmi Pharmaceutical — each target a different therapeutic frontier. Together they signal a deliberate strategy to expand beyond the blockbuster GLP-1 franchise that has been the company's primary growth engine.

Camurus: Amylin and Long-Acting Tech

Lilly exercised its option on Camurus' amylin receptor agonists, extending an existing collaboration into a third drug class. The expanded deal now covers up to four Lilly-owned compounds — dual GLP-1/GIP agonists, triple agonists, and amylin drugs — all delivered via Camurus' FluidCrystal platform. That technology uses naturally occurring lipids to release active ingredients over weeks from a single injection. For Camurus, the option exercise triggers an immediate $5 million payment, with up to $290 million in development milestones and another $580 million in sales-based payments, plus tiered mid-single-digit royalties.

Should investors sell immediately? Or is it worth buying Eli Lilly?

Haisco: A Billion-Dollar Bet on Chinese R&D

The Haisco deal underscores the rising importance of Chinese biotech. Lilly will pay $87 million upfront near term for access to up to five innovative target-discovery programs. Haisco handles early discovery and identification; Lilly takes over clinical development and commercialisation. The potential milestones approach $3 billion — a billion-dollar-plus pact that marks one of the largest China-US pharma collaborations in recent memory.

Hanmi: GLP-2 for Short Bowel Syndrome

The third agreement is a straight licensing play. Lilly secured global rights (excluding South Korea) to sonefpeglutide, a GLP-2 analogue developed on Hanmi's LAPSCOVERY platform. The candidate is currently in Phase 2 trials for short bowel syndrome, with Lilly exploring additional indications.

The three deals collectively show a company systematically building out its metabolic and immunology pipelines through Asian partnerships, while simultaneously adding infectious disease assets via vaccine acquisitions.

Oncology: ASCO Data Raises Questions — and Hopes

Separately, fresh Phase 1 data presented at the ASCO 2026 congress offered a glimpse of LY4052031, an experimental antibody-drug conjugate targeting Nectin-4 in advanced or metastatic urothelial carcinoma. The NEXUS-01 trial enrolled 137 patients, 107 of whom had metastatic disease, with a median of three prior treatments. Roughly two-thirds had previously received enfortumab vedotin.

In the key efficacy cohort — 48 patients without prior topoisomerase-I-ADC therapy and adequate CYP2D6 activity — the overall response rate hit 42%, with a disease control rate of 79%. Among the 36 patients who had previously received enfortumab vedotin, the response rate was 33%; in the highest tested dose of 3.6 mg/kg, it rose to 47%.

Eli Lilly at a turning point? This analysis reveals what investors need to know now.

The drug's mechanism differs from existing Nectin-4 ADCs: it couples a humanised antibody with a novel topoisomerase I inhibitor payload, potentially overcoming resistance to enfortumab-based regimens. Safety data showed elevated toxicity in patients with poor CYP2D6 metabolism, prompting mandatory genetic screening. In those with sufficient enzyme activity, side effects were mostly Grade 1 or 2: nausea, dysgeusia, alopecia, fatigue, anaemia, and constipation.

The stock took no cue from the oncology data — not surprising given that LY4052031 remains early-stage and plays a minor role in a valuation anchored by Mounjaro ($8.7 billion global revenue in Q1 2026) and Zepbound ($4.1 billion in the US). Lilly recently raised its full-year revenue guidance to $82-85 billion.

What's Next

Investors will get more clues on June 9, when CFO Kenneth Custer takes the stage for a fireside chat at the Goldman Sachs Healthcare Conference. With a share price just 4% below its 52-week high of €968.10 and an RSI of 94.6 signalling overbought conditions, the near-term direction may depend on whether management can articulate a pipeline narrative powerful enough to justify a market cap that already reflects enormous GLP-1 optimism.

Ad

Eli Lilly Stock: New Analysis - 2 June

Fresh Eli Lilly information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Eli Lilly analysis...

en | US5324571083 | ELI | boerse | 69467344 |